Mark Your Calendars, Biotech Investors

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Ever since Cell Therapeutics (Nasdaq: CTIC  ) decided to appeal the 2010 Food and Drug Administration rejection of its non-Hodgkin's lymphoma drug pixantrone, we've only heard the company's side of how the process was going -- not that the message was always clear. The FDA doesn't speak openly about drugs in the approval process.

But the FDA has finally spoken -- at least with its appointment calendar -- and it sure doesn't look like the appeal is going to be a straightforward process. Yesterday, Cell Therapeutics said that the FDA has scheduled an advisory panel meeting for Feb. 9.

My guess is that this isn't a good sign. If the appeal was going smoothly and the higher-ups at the agency had ordered the reviewers to accept Cell Therapeutics' explanation, there wouldn't seem to be much of a reason to hold an advisory-panel meeting. On the third-quarter conference call, CEO James Bianco pointed out the pickle it would put the FDA in: "It's difficult to see what it would be like to go back to panel in the setting of 'Oh, by the way, you saw this drug last year; we told you the trial failed. However, the company appealed and we now believe that the trial didn't fail.'"

In fact, advisory panels for second-attempt approvals are rare. MELA Sciences (Nasdaq: MELA  ) had one for its melanoma-detection device, MelaFind, but I'm fairly certain there wasn't one the first time around. Other controversial rejections like Dendreon's (Nasdaq: DNDN  ) Provenge didn't induce the agency to call one on its second -- successful, I might add -- attempt at an approval.

The optimists will say an advisory committee also means there's a chance for an approval. If there's a 100% chance the agency was going to reject the application again, why would it need an advisory-panel meeting? While that's a valid argument -- and I certainly wouldn't put the chance of rejection at 100% -- the agency may still be negative and just looking for some backing.

It may be wishful thinking on my part, but as much as the agency seems like a dictatorship sometimes, I get the feeling the leadership doesn't want to come across that way. The appeal process requires the agency to act as judge and jury, since Cell Therapeutics had to appeal the original decision back to the agency. By calling the advisory committee, the FDA can get a panel of outside experts to support its case and not look quite as tyrannical.

Of course, the Oncologic Drugs Advisory Committee reviewed pixantrone the first time as well, recommending 9-to-0 against approving the drug. So maybe the agency is just trying to share its tyrannical rule.

If you're looking for something a little less dependent on binary events for next year, check out the Fool's new free report, where Fool analysts report their top pick for 2012. Grab your free copy.

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 05, 2012, at 7:33 AM, Hufington wrote:

    "...and it sure doesn't look like the appeal is going to be a straightforward process. Yesterday, Cell Therapeutics said that the FDA has scheduled an advisory panel meeting for Feb. 9"

    ODAC panel review is the straightforward process for any cancer drug going through the approval process. How can you twist FDA protocol into a looming disaster for CTI, unless you have ulterior motives for driving this stock down?

  • Report this Comment On January 06, 2012, at 4:37 PM, TMFBiologyFool wrote:

    It's not straightforward for a second review. I don't know of any drugs that have had one for their resubmission.

    Straightforward would be the FDA agreeing with CTI and approving the drug without one.

    I don't own the stock and wouldn't short it either. Potential for a surprise approval may be small, but it would be extremely painful.

    Good luck with your gambling money.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1752413, ~/Articles/ArticleHandler.aspx, 10/22/2016 5:02:10 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,145.71 -16.64 -0.09%
S&P 500 2,141.16 -0.18 -0.01%
NASD 5,257.40 15.57 0.30%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/21/2016 4:00 PM
CTIC $0.40 Down -0.01 -1.44%
CTI BioPharma CAPS Rating: **
DNDNQ $0.00 Down +0.00 +0.00%
Dendreon Corp CAPS Rating: *
SSKN $0.49 Down -0.02 -3.92%
MELA Sciences CAPS Rating: *